Table 1 Patient characteristics
Baseline (n = 20) | Controls (n = 20) | p value | |
|---|---|---|---|
Age (years) | 61 ± 14 | 54 ± 9 | 0.07 |
Female, n (%) | 13 (65) | 10 (50) | 0.34 |
BMI (kg/m2) | 28 ± 6 | 24 ± 4 | < 0.05 |
NYHA I/II/III/IV, n (%) | 0/3/16/1(0/15/80/5) | ||
Arterial hypertension, n (%) | 9 (45) | ||
Atrial fibrillation, n (%) | 3 (15) | ||
COPD, n (%) | 7 (35) | ||
Diabetes mellitus, n (%) | 1 (5) | ||
Ischemic heart disease, n (%) | 0 | ||
Stroke, n (%) | 1 (5) | ||
Biochemistry | |||
NT-ProBNP (ng/l) | 890 [430; 2692] | ||
Hemoglobin (mmol/l) | 8.9 ± 1.4 | ||
Creatinine (µmol/l) | 85 ± 19 | ||
eGFR (ml/min) | 68 ± 14 | ||
Medicine | |||
Warfarin, n (%) | 20 (100) | ||
Aspirin, n (%) | 2 (10) | ||
ACE/ATII inhibitor, n (%) | 9 (45) | ||
Loop-diuretic, n (%) | 5 (25) | ||
Thiazide, n (%) | 4 (20) | ||
Spironolactone, n (%) | 2 (10) | ||
Sildenafil, n (%) | 1 (5) | ||
Riociguat, n (%) | 1 (5) | ||